Author(s):
Liver fibrosis research is advancing, focusing on noninvasive diagnostics, including serological markers and imaging, to personalize patient care [1]. Key areas involve understanding inflammation and Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH) in driving fibrosis, alongside exploring novel molecular, epigenetic, and gut microbiota-targeted therapies [2, 3, 4, 6, 8]. Biomarkers, Artificial Intelligence (AI), and single-cell sequencing are enhancing diagnostic precision and unraveling cellular complexities [5, 7, 9]. Despite ongoing challenges, future perspectives emphasize personalized medicine and integrated advanced technologies to improve management outcomes
